Stockscreener 앱 받기
1.29
2.27%
-0.03
Dermata Therapeutics Inc 주식(DRMA)의 최신 뉴스
Dermata Therapeutics Inc (DRMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
DRMA|Dermata Therapeutics Inc|Price:1.290|Chg%:-0.030 - TradingKey
Dermata Therapeutics Inc (DRMA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dermata Therapeutics, Inc. Revenue Breakdown – BOATS:DRMA - TradingView
TradingKey - TradingKey
Dermata Therapeutics, Inc. Revenue Breakdown – BOATS:DRMAW - TradingView
Price to earnings forward of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView
Price to sales forward of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView
Enterprise value to revenue forward of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView
Price to book forward of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView
DRMA Q1 2026 Earnings: EPS Surprise of 11.21% Beats Estimates Amid No Revenue GenerationDividend Earnings Report - dars.gov.et
Dermata Therapeutics Inc Warrant 2021- on Dermata Therapeutics Financial Disclosures & SEC Filings - TradingView
Dermata Therapeutics Warrant (DRMAW) Holds at $0.01 – Warrants Remain at Key Support LevelCombination Correction - dars.gov.et
Price to earnings forward of Dermata Therapeutics, Inc. – BOATS:DRMAW - TradingView
Dermata Therapeutics, Inc. Actuals & Estimates (NASDAQ:DRMA) - TradingView
Enterprise value to EBIT forward of Dermata Therapeutics, Inc. – NASDAQ:DRMA - TradingView
DRMA Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Dermata Therapeutics, Inc. – NASDAQ:DRMA - TradingView
Price to earnings forward of Dermata Therapeutics, Inc. – NASDAQ:DRMA - TradingView
Dermata Therapeutics Inc (DRMA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dermata Therapeutics Inc (DRMAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lixte Biotechnology Holdings, Inc. (LIXTW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Dermata Therapeutics Inc (DRMA) Institutional Confidence - TradingKey
Dermata Therapeutics Inc (DRMAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dermata Therapeutics Inc (DRMAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dermata Therapeutics Inc (DRMAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dermata Therapeutics Inc (DRMA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dermata Therapeutics Inc (DRMAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dermata Therapeutics Inc (DRMA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dermata Therapeutics Inc (DRMAW) Institutional Confidence - TradingKey
Dermata Therapeutics Inc (DRMA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dermata Therapeutics Inc (DRMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dermata Therapeutics Inc - TradingKey
Dermata Therapeutics Inc (DRMAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dermata Therapeutics Inc (DRMAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dermata Therapeutics (NASDAQ: DRMA) director reports small open-market stock sale - Stock Titan
Dermata Therapeutics Strategically Expands into Skincare with Executive Appointment - timothysykes.com
Dermata Therapeutics Poised for Expansion with Strategic Skincare Launch - timothysykes.com
Dermata Therapeutics Q1 2026 Earnings: EPS Surprise Beats Estimates Amid Pre-Revenue Biotech OperationsPost-Earnings Drift - dars.gov.et
Dermata Therapeutics Warrant (DRMAW) Slides 19.73% as Price Nears Critical Floor at $0.01Dark Pool Volume - newsline.com
DRMA Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Control Amid Pipeline ProgressQuarterly Financial Update - newsline.com
DRMA Q1 2026 Earnings: Better-than-Expected Loss Reduction Amidst Pipeline Development FocusShare Dilution Risk - newsline.com
DRMA Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Clinical Advances ContinueSlow Growth Warning - newsline.com
Dermata Therapeutics (DRMA) Edges Higher as Stock Tests Key Resistance LevelsVolume Climax - newsline.com
DRMA Q1 2026 Earnings: Positive EPS Surprise as Dermata Advances PipelinePreliminary Results - newsline.com
CFO Kyri Van Hoose (DRMA) discloses 9% Dermata ownership in Schedule 13D - Stock Titan
[EFFECT] Dermata Therapeutics, Inc. SEC Filing - Stock Titan
Dermata Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Dermata Therapeutics Warrant (DRMAW) Holds at Penny Level – Key Levels to WatchPoint of Control - newsline.com
Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf registration - Stock Titan
Dermata Therapeutics (DRMA) Stages Modest Recovery – Support Holds Above $1.28Keltner Channel - The Legal Advocate
Dermata Therapeutics (DRMA) Shares Climb 3.85% as Stock Tests Key Resistance LevelsVolume Breakout Ideas - The Legal Advocate
Dermata Therapeutics Adopts Fourth Amendment to 2021 Omnibus Equity Incentive Plan – Form 8-K Filing Summary - Minichart
Dermata Therapeutics Shareholders Approve Equity Plan and Directors - TipRanks
Dermata (NASDAQ: DRMA) investors approve equity plan expansion and warrant changes - Stock Titan
DRMADermata Therapeutics Inc Stock Price and Quote - Finviz
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
DRMA Q1 2026 Earnings: Narrower Loss Than Expected Bolsters Investor SentimentRevenue Report - Newser
Dermata Therapeutics (DRMA) Q1 2026 Earnings: Narrower Loss Surprises as Pre-Revenue Biotech Continues Pipeline ProgressFinancial Health Score - dars.gov.et
1.97%
0.83%
자본화:
|
볼륨(24시간):